BR9910609A - 4-fenilpiperidinas para o tratamento de dermatoses prurìticas - Google Patents

4-fenilpiperidinas para o tratamento de dermatoses prurìticas

Info

Publication number
BR9910609A
BR9910609A BR9910609-4A BR9910609A BR9910609A BR 9910609 A BR9910609 A BR 9910609A BR 9910609 A BR9910609 A BR 9910609A BR 9910609 A BR9910609 A BR 9910609A
Authority
BR
Brazil
Prior art keywords
treatment
pruritic dermatoses
phenylpiperidines
useful
pruritic
Prior art date
Application number
BR9910609-4A
Other languages
English (en)
Inventor
Richard Edward Armer
Christopher James Dutton
David Morris Gethin
Stephen Paul Gibson
Julian Duncan Smith
Ivan Tommasini
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of BR9910609A publication Critical patent/BR9910609A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • C07D211/28—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/94—Oxygen atom, e.g. piperidine N-oxide

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Patente de Invenção: <B>"4-FENILPIPERIDINAS PARA O TRATAMENTO DE DERMATOSES PRURìTICAS"<D>. Novos compostos que têm a fórmula geral (I): e seus sais farmaceuticamente e veterinariamente aceitáveis em que R¹, R², R³, W, Y¹, Y², X, n e y são conforme acima definidos e processos para a sua preparação e compostos intermediários aqui preparados. Os novos compostos são úteis por terem utilidade no tratamento de dermatoses pruríticas incluindo dermatite alérgica e atopia em animais e humanos.
BR9910609-4A 1998-05-18 1999-05-17 4-fenilpiperidinas para o tratamento de dermatoses prurìticas BR9910609A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9810671.9A GB9810671D0 (en) 1998-05-18 1998-05-18 Anti-pruritic agents
PCT/IB1999/000886 WO1999059971A1 (en) 1998-05-18 1999-05-17 Novel 4-phenylpiperidines for the treatment of pruritic dermatoses

Publications (1)

Publication Number Publication Date
BR9910609A true BR9910609A (pt) 2001-01-09

Family

ID=10832267

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9910609-4A BR9910609A (pt) 1998-05-18 1999-05-17 4-fenilpiperidinas para o tratamento de dermatoses prurìticas

Country Status (18)

Country Link
US (1) US6610711B2 (pt)
EP (1) EP1077940B1 (pt)
JP (1) JP2002515486A (pt)
AP (1) AP9901535A0 (pt)
AT (1) ATE271038T1 (pt)
AU (1) AU3531299A (pt)
BR (1) BR9910609A (pt)
CA (1) CA2332538C (pt)
DE (1) DE69918687T2 (pt)
DK (1) DK1077940T3 (pt)
ES (1) ES2230846T3 (pt)
GB (1) GB9810671D0 (pt)
GT (1) GT199900067A (pt)
MA (1) MA26630A1 (pt)
PT (1) PT1077940E (pt)
TN (1) TNSN99095A1 (pt)
WO (1) WO1999059971A1 (pt)
ZA (1) ZA993364B (pt)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9912410D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
GB9912413D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
GB9912416D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
GB9912417D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
GB9912411D0 (en) * 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
GB9912415D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
US6727264B1 (en) 2001-07-05 2004-04-27 Synaptic Pharmaceutical Corporation Substituted anilinic piperidines as MCH selective antagonists
CN1671386A (zh) * 2001-07-05 2005-09-21 H·隆德贝克有限公司 作为mch选择性拮抗剂的取代苯胺基哌啶
DE60226161T2 (de) * 2001-10-22 2009-07-02 Pfizer Products Inc., Groton 3-azabicyclo[3.1.0]hexan derivative als antagonisten der opioid rezeptoren
US7338965B2 (en) * 2001-11-19 2008-03-04 Pharmacia & Upjohn Company 3,4-disubstituted, 3,5-disubstituted and 3,4,5-substituted piperidines
ES2201908B1 (es) * 2002-05-29 2005-02-16 Laboratorios Del Dr. Esteve, S.A. Pienso suplementado con ketoprofeno y su empleo en el tratamiento de procesos que cursan con fiebre, inflamacion y/o dolor, en un colectivo de animales, de forma simultanea.
BRPI0409307A (pt) * 2003-04-14 2006-04-25 Pfizer Prod Inc derivados de 3-azabiciclo[3.2.1]octano
FR2872416B1 (fr) * 2004-07-01 2006-09-22 Oreal Utilisation de derives de piperidine pour lutter contre les rides
EP2767163A1 (en) * 2005-02-17 2014-08-20 Abbott Laboratories Transmucosal administration of drug compositions for treating and preventing disorders in animals
JP2009519349A (ja) * 2005-12-15 2009-05-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｂ２受容体を変調する化合物
MY145633A (en) 2006-03-01 2012-03-15 Theravance Inc 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists
EP2081905B1 (en) * 2006-07-28 2012-09-12 Boehringer Ingelheim International GmbH Sulfonyl compounds which modulate the cb2 receptor
CN101516839A (zh) * 2006-09-25 2009-08-26 贝林格尔.英格海姆国际有限公司 调节cb2受体的化合物
TWI409067B (zh) * 2007-02-28 2013-09-21 Theravance Inc ８-氮雜雙環〔３．２．１〕辛烷化合物之結晶型
ES2390195T3 (es) * 2007-08-27 2012-11-07 Theravance, Inc. Compuestos de amidoalquil-8-azabiciclo(3,2,1)octano, como antagonistas del receptor opioide mu
US7691878B2 (en) * 2007-08-27 2010-04-06 Theravance, Inc. Heteroarylalkyl-8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists
US7947710B2 (en) * 2007-08-27 2011-05-24 Theravance, Inc. Disubstituted alkyl-8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists
TWI423801B (zh) 2007-08-27 2014-01-21 Theravance Inc 作為μ類鴉片受體拮抗劑之８－氮雜雙環〔３．２．１〕辛基－２－羥基苯甲醯胺化合物
JP5492092B2 (ja) * 2007-11-07 2014-05-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｂ２受容体を調節する化合物
JP5749162B2 (ja) * 2008-07-10 2015-07-15 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｂ２受容体を調節するスルホン化合物
BRPI0919172A2 (pt) * 2008-09-25 2015-12-15 Boehringer Ingelheim Int compostos os quais modulam seletivamente o receptor de cb2
US8299103B2 (en) 2009-06-15 2012-10-30 Boehringer Ingelheim International Gmbh Compounds which selectively modulate the CB2 receptor
EP2443107B1 (en) 2009-06-16 2018-08-08 Boehringer Ingelheim International GmbH Azetidine 2 -carboxamide derivatives which modulate the cb2 receptor
WO2011037795A1 (en) * 2009-09-22 2011-03-31 Boehringer Ingelheim International Gmbh Compounds which selectively modulate the cb2 receptor
WO2011088015A1 (en) 2010-01-15 2011-07-21 Boehringer Ingelheim International Gmbh Compounds which modulate the cb2 receptor
US8329735B2 (en) 2010-03-05 2012-12-11 Boehringer Ingelheim International Gmbh Tetrazole compounds which selectively modulate the CB2 receptor
EP2595959B1 (en) 2010-07-22 2015-11-04 Boehringer Ingelheim International GmbH Sulfonyl compounds which modulate the cb2 receptor
EP2803668A1 (en) 2013-05-17 2014-11-19 Boehringer Ingelheim International Gmbh Novel (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles
CN106278914B (zh) * 2016-08-19 2018-04-13 四川福思达生物技术开发有限责任公司 一种增产胺的合成工艺

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR206937A1 (es) 1974-09-06 1976-08-31 Lilly Co Eli Procedimiento para preparar compuestos de 1-sustituido-4-alquil-4-fenil-piperidina
IL86061A (en) * 1987-04-16 1992-07-15 Lilly Co Eli Derivatives of trans-3,4-isomer of 4-methyl-4-phenyl-piperidines,process for their preparation and pharmaceutical compositions containing them
NZ242117A (en) * 1991-03-29 1994-11-25 Lilly Co Eli 4-phenylpiperidine derivatives and medicaments containing them
US5159081A (en) * 1991-03-29 1992-10-27 Eli Lilly And Company Intermediates of peripherally selective n-carbonyl-3,4,4-trisubstituted piperidine opioid antagonists
GB9507203D0 (en) * 1995-04-07 1995-05-31 Smithkline Beecham Plc Novel compounds
DZ2376A1 (fr) * 1996-12-19 2002-12-28 Smithkline Beecham Plc Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.
EP0975614A1 (en) * 1997-04-18 2000-02-02 Smithkline Beecham Plc A bicyclic aryl or a bicyclic heterocyclic ring containing compounds having a combined 5ht1a, 5ht1b and 5ht1d receptor antagonistic activity

Also Published As

Publication number Publication date
CA2332538A1 (en) 1999-11-25
ATE271038T1 (de) 2004-07-15
GT199900067A (es) 2000-11-04
AP9901535A0 (en) 1999-06-30
US6610711B2 (en) 2003-08-26
DK1077940T3 (da) 2004-11-01
DE69918687D1 (de) 2004-08-19
US20030078282A1 (en) 2003-04-24
EP1077940A1 (en) 2001-02-28
WO1999059971A1 (en) 1999-11-25
EP1077940B1 (en) 2004-07-14
PT1077940E (pt) 2004-10-29
MA26630A1 (fr) 2004-12-20
CA2332538C (en) 2005-08-02
GB9810671D0 (en) 1998-07-15
DE69918687T2 (de) 2005-07-28
ES2230846T3 (es) 2005-05-01
ZA993364B (en) 2000-12-01
JP2002515486A (ja) 2002-05-28
TNSN99095A1 (fr) 2005-11-10
AU3531299A (en) 1999-12-06

Similar Documents

Publication Publication Date Title
BR9910609A (pt) 4-fenilpiperidinas para o tratamento de dermatoses prurìticas
BR0109703A (pt) Derivados de piperazina
WO2001042231A3 (en) Polyhydroxystilbenes and stilbene oxides as antisoriatic agents and protein kinase inhibitors
NO331013B1 (no) Nye forbindelser som er anti-inflammasjons, immunomodulerende og anti-proliferative midler, anvendelse av forbindelsene samt farmasoytisk preparat
BR0113176A (pt) Compostos biciclo-pirazol, composições farmacêuticas compreendendo os compostos, uso dos compostos na fabricação de medicamentos, processos para a preparação dos compostos, coleção quìmica combinatória e métodos para o tratamento de mamìferos incluindo humanos utilizando os compostos
SE0102315D0 (sv) Compounds
CY1105362T1 (el) Παραγωγα σουλφοναμιδιου, η παρασκευη τους και η εφαρμογη αυτων ως φαρμακα
CY1107539T1 (el) Παραγωγα κουιναζολινης
JO2371B1 (en) 4-phenyl-pyridine derivatives
NO20055219L (no) Nye forbindelser
NO20042298L (no) Farmasoytiske preparater og deres anvendelser
CR6540A (es) Trifluorobutenos nematicidas
CY1108295T1 (el) Παραγωγα μονοσακχαριτη αβερμεκτινης τα οποια εχουν παρασιτοκτονες ιδιοτητες
ATE452129T1 (de) N-phenyl-2-pyrimidine-amine derivatives
CY1111693T1 (el) Αντιιικοι παραγοντες
CY1105221T1 (el) Ιατρικη χρηση θυρεοειδομιμητικων ενωσεων για την θepαπευτικη αγωγη της τριχοπτωσης και φαρμακευτικες συνθεσεις
NO20081482L (no) Delta- og epsilon-krystallformer for imatinibmesylat
BR0314220A (pt) Compostos de benzotriazol-1-il-aminoacetonitrila e seu uso no controle de doença provocada por parasitas
BR0209127A (pt) compostos, composições farmacêuticas, métodos para o tratamento de dores, métodos para a modulação de uma resposta farmacológica e usos de compostos
BR0214876A (pt) Formas de sal de e-2-metóxi-n-(3-(4-(3-metil-piridin-3-ilóxi)-fenilamino)qui nazolin-6-il)-alil)-acetamida, suas preparações e uso dos mesmos contra o câncer
BR0309342A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas
BR0113590A (pt) 7-oxo-piridopirimidinas
EA200301203A1 (ru) Новые соединения и композиции как ингибиторы катепсина
BR0208499A (pt) ácido 3-heterociclilpropanohidroxâmico como inibidores de procolágeno c-proteinase
NO20010940D0 (no) TAN-1057 derivater

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A E 9A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 1945 DE 15 - 04 - 2008.